Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
STAT

EU and US advisers split over AstraZeneca breast cancer drug

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The ...

Merck Secures EU Backing for Keytruda-Padcev in Bladder Cancer Patients Subset

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

Moderna, Merck cancer combo cuts melanoma spread risk at five years

May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...